Latest Conference Articles

Dr. Keith Flaherty Discusses Long-Term Data from the COLUMBUS Trial

Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

Bin Zheng on the Potential of Diabetes Drugs in Melanoma

Bin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.

Encorafenib/Binimetinib Highly Effective in BRAF-mutant Melanoma

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib (Zelboraf) for patients with BRAF-mutant unresectable melanoma.

Nilotinib/Trametinib Show Early Promise in BRAF/NRAS Wild-Type Melanoma

The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma.

Dabrafenib/Trametinib OS Duration Associated With Number of Metastatic Melanoma Sites

The combination of dabrafenib and trametinib continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with baseline site of metastasis identified as a predictor of overall survival ≥36 months,

Graham Mann on Genetic Mutations in Different Types of Melanoma

Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.

Stefani Spranger Explores the Absence of T Cells in Melanoma Subtypes

Stefani Spranger, PhD, postdoctoral fellow at the University of Chicago, discusses recent findings about why a certain subgroup of patients with melanoma do not have T cells within their tumor microenvironment.

Expert Highlights Resistance to Targeted Therapies, Role of Epigenetic Changes in Melanoma

Helmut Schiader, MD, discusses why drug resistance may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.

Immunotherapy, MEK Inhibitor Combo Effective for BRAF Wild-Type Melanoma

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Dr. Christian Blank on Combining Immunotherapy Agents in High-Risk Melanoma

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.

Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma

Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.

Experts Provide Tips on Setting Up a Successful Community-Based Clinical Trials Program

Clinical research in private practice is thriving and the future is bright.

Dr. Ryan Sullivan on Treating BRAF-Mutant Patients With Melanoma

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.

LUGPA Will Create Bundled Payment Models for Prostate Care

The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.

Expert Emphasizes Impact of Robotic Surgery in Field of Prostate Cancer

David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.

Atezolizumab Combos Highly Effective for Advanced Melanoma

The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with BRAF-mutant unresectable melanoma.

Dr. Concepcion on the Use of Eligard in Prostate Cancer Treatment

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

Dr. Buffington on The Use of Fusion MRI in Prostate Cancer

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.

Potential for Neoadjuvant Immunotherapy in Bladder Cancer Is Wide Open, Expert Says

With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.

Nimble, Larger Practices Can Thrive Under New Healthcare Delivery Models

Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.

Dr. David Albala on The Role of Robotic Surgery in Prostate Cancer

Systemic Immunotherapy Use Expanding Rapidly in Bladder Cancer

Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.

Lenvatinib Regimen Setting Pace for Emerging Combos in Kidney Cancer

The dual inhibitor combination of lenvatinib and everolimus is becoming an essential second-line treatment option in advanced renal cell carcinoma, and research to move the regimen into frontline settings is underway.

Novel Therapies Offer Hope for BCG-Unresponsive Bladder Cancer

A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.

RCC Experts Consider Immunotherapy Integral to Optimizing Adjuvant Care

Looking ahead to 2020, most participants on an expert panel projected that immunotherapy will be critical to optimizing outcomes in the adjuvant setting for patients with renal cell carcinoma.

Bladder Cancer Biomarkers Aid in Diagnosis, Monitoring

When it comes to the burgeoning arena of biomarkers in bladder cancer, the value proposition is compelling, although the utility and costs need to be better defined, according to Badrinath Konety, MD, MBA.

Cabozantinib Benefits Similar in MET Expressing Advanced RCC

Cabozantinib demonstrated consistent benefits compared with everolimus for patients with advanced, pretreated renal cell carcinoma in a subgroup analysis of the phase III METEOR trial that explored MET expression.

Dr. Hutson on Lenvatinib/Everolimus Combo in RCC

Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).

Dr. Haas on Adjuvant VEGF-Targeted Therapy in RCC

Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).

Expert Examines Conflicting Adjuvant RCC Results

Conflicting results from large adjuvant studies for renal cell carcinoma may have been caused by differences between the clinical trial designs, patient populations, and assessment criteria.